Impact of STAT3 Inhibition on Tumour Progression and Immune Evasion in Non-Small Cell Lung Cancer

Signal Transducer and Activator of Transcription 3 (STAT3) is a critical transcription factor that regulates cell growth, survival and immune responses. It is implicated in Non-Small Cell Lung Cancer (NSCLC), the most prevalent form of lung cancer categorized by aggressive tumour progression and high metastatic potential. NSCLC’s aggressiveness stems from the overactivation of STAT3, promoting cancer cell proliferation, survival, and invasion through mechanisms including genetic mutations, cytokine signalling and inflammatory pathways within the tumour microenvironment. This heightened STAT3 activity not only supports tumour growth but also suppresses anti-tumour immune responses and fosters an immunosuppressive environment. Currently, treatment for NSCLC patients involves cancer therapies that reduce tumour cell proliferation. This study investigates the impact of STAT3 inhibition in NSCLC that suppresses the anti-tumour immunity and epithelial-mesenchymal transition in the cancer cells. This article utilizes the PubMed database to retrieve a total of twenty articles regarding the effects of STAT3 on cell growth and metastasis, specific STAT3 inhibitors such as W2014-S, IL-37, MicroRNA-148a, RITA and WP1066, and investigating their effects on NSCLC. Inhibiting STAT3 reduces tumour cell proliferation while enhancing T-cell activation and reducing immunosuppressive factors within the tumour microenvironment. Some studies observed the role of STAT3 inhibitors with both in vitro and in vivo samples, highlighting the therapeutic potential. STAT3 clearly has a crucial role in aggressive pathogenesis seen in NSCLC due to increased immune evasion; thus, the inhibition would help reduce the tumour invasiveness, offering a promising therapeutic approach to mitigate NSCLC progression and enhancing the efficacy of existing treatments.